SELEXON
Live / Allowed — Notice of allowance issued (as of 14 Jul 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 26 Nov 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99518932
- Mark type
- Word mark
- Filed
- 26 Nov 2025
- Published for opposition
- 19 May 2026
- Attorney of record
- Michael Graif
Goods and services
- Class 005 — Pharmaceuticals: Gene therapy products, namely, components of cells for medical use that restrict expression to specific cells through the use of alternative splicing
- Class 042 — Scientific and technological services: Gene therapy research in the field of restricting cell expression to specific cells through the use of alternative splicing
Owner
- Aletira Therapeutics, Inc., Baltimore, MD, US
- Aletira Therapeutics, Inc., Baltimore, MD, US
Prosecution history
- 14 Jul 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 19 May 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 May 2026 — PUBLISHED FOR OPPOSITION
- 13 May 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Apr 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Apr 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Apr 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 Apr 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 13 Apr 2026 — NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
- 13 Apr 2026 — EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
- 13 Apr 2026 — COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
- 13 Apr 2026 — EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
- 31 Mar 2026 — ASSIGNED TO EXAMINER
- 26 Nov 2025 — APPLICATION FILING RECEIPT MAILED
- 26 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED